Shire Continues to Deliver Excellent Growth From Cor...(- 1.0 0.5 ...),Health

Date:10/30/2009

- 1.0 0.5 1.8 Proceeds/deposits received on sales of product rights - - - 5.0 Proceeds from disposal of subsidiary undertakings - - 6.7 - Returns from equity investments - - 0.2 0.4 Net cash used in investing activities(B) (71.9) (561.3) (235.4) (630.1) CASH FLOWS FROM FINANCING ACTIVITIES: Payment under building financing obligation (0.9) (0.9) (3.9) (1.3) Costs of issue of common stock - (0.1) - (2.9) Proceeds from exercise of options 1.8 0.7 2.8 1.7 Payment of dividend - - (43.0) (36.4) Payments to acquire shares by Employee Share Ownership Trust ("ESOT") - (36.2) (1.0) (140.2) Net cash provided by/(used in) financing activities(C) 0.9 (36.5) (45.1) (179.1) Effect of foreign exchange rate changes on cash and cash equivalents (D) 6.4 (9.5) 5.0 (5.5) Net increase/(decrease) in cash and cash equivalents (A)+(B)+(C)+(D) 69.4 (327.9) 114.5 (289.2) Cash and cash equivalents at beginning of period 263.3 801.2 218.2 762.5 Cash and cash equivalents at end of period 332.7 473.3 332.7 473.3 Unaudited US GAAP results for the three months and nine months to September 30, 2009 Selected Notes to the Financial Statements (1) Earnings per share 3 months 3 months 9 months 9 months
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease